Table 2 Clinical and laboratory data of the study groups.
From: Characterization of two types of intranuclear hepatocellular inclusions in NAFLD
Characteristics | Control (n = 19) | NAFL (n = 23) | NASH (n = 35) | n valid cases | P value* |
|---|---|---|---|---|---|
Age (years) | 45 (1–80) | 38 (24–67) | 45 (20–67) | 23/35 | 0.242 |
Gender (male/female) | 10/9 | 4/19 | 14/21 | 23/35 | 0.087 |
BMI (kg/m2) | 23 (13–44) | 49.9 (29.4–66.9) | 52.9 (27.4–78.2) | 21/33 | 0.231 |
Adiponectin (µg/mL) | – | 3.1 (1.3–8.3) | 2.95 (0.83–11.9) | 21/25 | 0.991 |
CK18 M30 (IU/L) | – | 184.9 (61.8–807.7) | 367.6 (80.1–1,573.9) | 21/25 | 0.001 |
CK18 M65 (IU/L) | – | 333.4 (87.9–960.1) | 636.7 (255.8–5,273.1) | 20/25 | < 0.001 |
Fasting glucose (mg/dl) | – | 96.00 (73–150) | 126 (72–385) | 23/31 | 0.001 |
Total cholesterol (mg/dl) | – | 198 (120–261) | 177.5 (116–247) | 15/18 | 0.320 |
Triglyceride (mg/dl) | – | 149 (34–218) | 207 (55–421) | 13/12 | 0.041 |
ALT (U/L) | 52 (9–3,272) | 21 (13–65) | 39 (14–120) | 23/33 | < 0.001 |
AST (U/L) | 86 (20–3,078) | 23 (16–49) | 34 (23–90) | 15/21 | < 0.001 |
GGT (U/L) | 135 (0–743) | 20 (1.5–93) | 41 (14–1,213) | 23/33 | < 0.001 |
Fibrosis grade | |||||
0/1 | – | 4/7 | 6/9 | ||
2/3 | – | 10/2 | 18/2 | 23/35 | 0.79 |
Steatosis grade | |||||
0/1 | 19/0 | 0/20 | 0/8 | ||
2/3 | 0/0 | 3/0 | 15/12 | 23/35 | < 0.001 |
Ballooning grade | |||||
0/1 | 19/0 | 18/3 | 0/18 | ||
2 | 0 | 2 | 17 | 23/35 | 0.002 |
Lob. Inflam. grade | |||||
0/1 | 19/0 | 16/4 | 0/12 | ||
2/3 | 0/0 | 3/0 | 21/2 | 23/35 | < 0.001 |
